Skip to content

Damora Therapeutics

US · DMRA #3109 by market cap Listed 1970
23.22 -1.08 -4.44%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 23.98 -1.32%
After-hours 23.22 0.00%
Overnight 24.00 -1.23%
32.9918.4323.222026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on DMRA?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is +5.2% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 7.6% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall C-

The radar needs all six factors. Available grades are shown below.

Valuation C-

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 13.6x Better than 63%
P/E vs own 5-yr range 99th pctl Better than 3%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Return on equity -91.6% Better than 6%
Return on invested capital -94.6% Better than 2%
Momentum C+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -24.7% Better than 24%
6-month return -8.2% Better than 42%
12-month return (ex latest month) 25.8% Better than 65%
Distance below 52-week high 39.4% Better than 29%
Financial Health A

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 13.0x Better than 95%
Debt to assets 0.0% Better than 99%
Interest coverage -4.3x Better than 17%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 101.0% Better than 84%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W +7.50%
1M +12.34%
3M -23.39%
6M -3.85%
YTD +0.91%
1Y +33.83%
3Y +57.42%
5Y -69.04%

Key statistics

Price & volume

Prev close
24.30
Open
23.81
Day range
23.13 - 24.51
Avg price
23.58
Volume
643.38K
Turnover
15.17M
Amplitude
5.70%
52-week range
15.76 - 38.33

Valuation

P/E
-5.83
P/E (TTM)
13.58
P/B
3.93
EPS
-3.98
Net profit
-246.38M
Net assets
365.80M

Share structure

Market cap
1.44B
Float cap
964.92M
Shares out
61.90M
Float shares
41.56M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 33% of range
15.76 38.33

39.4% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-4.02M net over the window

Short interest

Shares short
4.69M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Damora Therapeutics (DMRA)?

Damora Therapeutics last traded at 23.22. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Damora Therapeutics's market cap?

About 1.44B.

What is the P/E ratio of Damora Therapeutics?

The trailing twelve-month P/E is 13.58. The Valuation tab shows it against the stock's own five-year range.

Does Damora Therapeutics pay a dividend?

Damora Therapeutics does not currently pay a regular dividend.

Is Damora Therapeutics a buy according to analysts?

The consensus of 6 analysts is a Buy rating, with an average 12-month price target of 46.67, which implies 101.0% upside from the current price. This is not investment advice.

What is Damora Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Damora Therapeutics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Damora Therapeutics discussion 0 comments

Add a comment